Terumo Medical Corporation Obtains Withdrawal by Vascular Solutions of the R-Band&#0153 Radial Hemostasis Device

SOMERSET, N.J., May 21, 2013 /PRNewswire/ -- Terumo Medical Corporation (Terumo), today announced that it was pleased with the U.S. District Court for the District of New Jersey's Order approving an agreement of the parties under which Vascular Solutions Inc. will cease further manufacture, sales, and distribution of its R-Band Radial Hemostasis Device, pending litigation of Terumo's claims.

In February, Terumo filed a patent infringement lawsuit alleging that the R Band Radial Hemostasis Device infringes on U.S. patent and trademark rights held by Terumo Medical Corporation for its proprietary TR Band Radial Compression Device. The R-Band is distributed in the U.S. by Vascular Solutions and manufactured by Lepu Medical Technology. Terumo sought an injunction against further sales of the infringing product.

"Terumo is extremely gratified with the Court's Order. We are thankful for the opportunity to successfully defend our TR Band device, which is a critical part of our transradial solutions portfolio," said James Rushworth, President, Terumo Interventional Systems and Onset Medical Corporation. "As a market leader, Terumo is committed to doing what is right for our business and, when appropriate, we will vigorously protect our investments, assets and intellectual property."

Terumo's market-leading TR Band Radial Compression Device is used to achieve patent hemostasis immediately following a transradial access diagnostic and intervention in the treatment of cardiac and vascular disease. The clear band is placed around the patient's wrist to effectively stop access-point bleeding. The TR Band features dual compression balloons that maintain precise pressure on the radial artery to ensure blood return without compromising local nerve structure. Transradial access interventions have been shown to significantly reduce bleeding complications by up to 75 percent when compared to femoral (through the groin) interventions.

Terumo Interventional Systems
Terumo Interventional Systems (TIS) is a strategic business unit of Terumo Medical Corporation. As a market leader in entry site management and lesion access, TIS is committed to pursuing unique technologies designed to enhance treatment of coronary and peripheral endovascular diseases as well as driving strategic initiatives focused on Critical Limb Ischemia, Complex Coronary Intervention and Transradial Access. Terumo® Urology, a dedicated group within TIS, focuses on direct sales, marketing, support and distribution of key products to the urological specialty.

TIS directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.

Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets a complete, solutions-based portfolio of high-quality medical devices used in a broad range of applications for numerous areas of the healthcare industry. TMC is comprised of two business divisions: Terumo Interventional Systems and Terumo Medical Products. The company places a premium on providing customers with world-class products, training and education programs that drive clear economic value, better clinical outcomes and improved Quality of Life for patients.

Terumo Corporation
Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with $5 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve.

Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

SOURCE Terumo Medical Corporation